Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Receivables (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Change in Receivables for 3 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 253.98% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, down 40.59% year-over-year, with the annual reading at $7.3 million for FY2025, 40.59% down from the prior year.
  • Change in Receivables hit -$2.0 million in Q4 2025 for Immunocore Holdings, down from $6.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $10.2 million in Q4 2023 to a low of -$2.0 million in Q4 2025.
  • Historically, Change in Receivables has averaged $3.1 million across 3 years, with a median of $3.1 million in 2023.
  • Biggest five-year swings in Change in Receivables: surged 365.39% in 2024 and later tumbled 253.98% in 2025.
  • Year by year, Change in Receivables stood at $10.2 million in 2023, then crashed by 87.33% to $1.3 million in 2024, then crashed by 253.98% to -$2.0 million in 2025.
  • Business Quant data shows Change in Receivables for IMCR at -$2.0 million in Q4 2025, $6.0 million in Q3 2025, and $4.2 million in Q2 2025.